Trial · NCT07907081
Comparative Analysis of Chamomile Tea (Matricaria Chamomilla) and Green Tea (Camellia Sinensis) Against Hyperlipidemia
NCT07907081, Not applicable, Completed, Iahtisham-Ul-Haq
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparative Analysis of Chamomile Tea (Matricaria Chamomilla) and Green Tea (Camellia Sinensis) Against Hyperlipidemia. Trials, record NCT07907081. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07907081
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparative Analysis of Chamomile Tea (Matricaria Chamomilla) and Green Tea (Camellia Sinensis) Against Hyperlipidemia
- NCT number
- NCT07907081
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 25 participants, actual
- Lead sponsor
- Iahtisham-Ul-Haq
- Conditions
- Hyperlipidemia, Normal
- Interventions
- Chamomile tea (Matricaria chamomilla), Green tea (Camellia sinensis)
- First posted
- 2026-10-30
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum Low-density lipoprotein (LDL) cholesterol concentration (milligrams per deciliter) | Baseline and 30 days | LDL was measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics |
| Primary | Serum High-density lipoprotein (HDL) cholesterol concentration (milligrams per deciliter) | Baseline and 30 days | HDL was measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics |
| Primary | Serum Very low-density lipoprotein (VLDL) cholesterol concentration (milligrams per deciliter) | Baseline and 30 days | VLDL was measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics |
| Primary | Serum total cholesterol concentration (milligrams per deciliter) | Baseline and 30 days | Total cholesterol was measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics. |
| Primary | Serum triglycerides concentration (milligrams per deciliter) | Baseline and 30 days | Triglycerides were measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics |
| Secondary | Fasting Blood Glucose concentration (milligrams per deciliter) | Baseline and 30 days | Fasting Blood Glucose was measured by using enzymatic method in Roche Modular P chemistry analyzer |
| Secondary | Serum alanine aminotransferase (ALT) concentration (milligrams per deciliter) | Baseline and 30 days | ALT was measured by using Hitachi 704 analyzer serviced by Roche diagnostics |
| Secondary | Serum aspartate aminotransferase (AST) concentration (milligrams per deciliter) | Baseline and 30 days | AST was measured by using Hitachi 704 analyzer serviced by Roche diagnostics |
| Secondary | Serum alkaline phosphatase (ALP) concentration (milligrams per deciliter) | Baseline and 30 days | ALP was measured by using Hitachi 704 analyzer serviced by Roche diagnostics |
| Secondary | Serum bilirubin concentration (milligrams per deciliter) | Baseline and 30 days | Bilirubin was measured by using Hitachi 704 analyzer serviced by Roche diagnostics |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07907081
GET https://conductscience.org/api/trials/v1/NCT07907081/registered